For much of the history of modern cancer treatment, oncologists had few means to predict the potential efficacy of treatment beyond tumor staging. Overcoming that challenge started with the Human Genome Project, a massive international public health initiative to sequence the 3 billion base pairs in the human genome that began in 1990 and was completed in 2003.1
Based on the results of the Human Genome Project, alongside advances in research technology, the focus of cancer treatment evolved beyond the blanket approach to emphasize precision medicine.2 Precision medicine (also referred to as "personalized medicine") incorporates information specific to the individual patient, such as genetic or biomarker-expression profiles, to guide cancer therapy.
Precision medicine is a cornerstone of modern cancer therapy, with diagnostic, predictive, prognostic, and disease-monitoring biomarkers guiding therapy across tumor types.3 However, significant treatment challenges remain as clinical experience with and understanding of precision medicine matures.2,3
AbbVie is fully committed to expanding and enhancing the utility of precision medicine by exploring the potential of advanced research and drug technologies to overcome current treatment challenges. This effort includes:
The site you have requested is intended to provide information for healthcare professionals residing in the US or Puerto Rico.
I am a licensed healthcare professional residing in the US or Puerto Rico.
I am not a licensed healthcare professional residing in the US or Puerto Rico.
Contact Medical Information
For All Other Information